Yahoo
OTC Markets OTCQX - Delayed Quote USD

Cresco Labs Inc. (CRLBF)

0.5734 -0.0565 (-8.97%)
At close: 3:59:15 PM EDT
Chart Range Bar
Loading chart for CRLBF
  • Previous Close 0.6299
  • Open 0.6000
  • Bid 0.5731 x 120000
  • Ask 0.5915 x 2000000
  • Day's Range 0.5721 - 0.6187
  • 52 Week Range 0.5540 - 2.3000
  • Volume 104,505
  • Avg. Volume 539,467
  • Market Cap (intraday) 212.296M
  • Beta (5Y Monthly) 1.81
  • PE Ratio (TTM) --
  • EPS (TTM) -0.3800
  • Earnings Date Nov 6, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 2.00
  • Zacks Rating Neutral

Cresco Labs Inc. cultivates, manufactures, and sells retail and medical cannabis products in the United States and Germany. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes, gummies, and pre-rolls under the Good News brand; vapes and edibles under the Wonder Wellness Co. brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand. The company offers cannabis flowers under the FloraCal brand; and cannabis oils and variety of bites are available at multiple potency levels under the Mindy's brand, as well as Loud*r brand. In addition, the company offers cannabis-infused edibles under the Sunnyside brand. The company is headquartered in Chicago, Illinois.

www.crescolabs.com

2,900

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .

YTD Return

CRLBF
53.00%
S&P/TSX Composite index (^GSPTSE)
11.78%

1-Year Return

CRLBF
49.70%
S&P/TSX Composite index (^GSPTSE)
18.03%

3-Year Return

CRLBF
48.11%
S&P/TSX Composite index (^GSPTSE)
88.90%

5-Year Return

CRLBF
92.65%
S&P/TSX Composite index (^GSPTSE)
69.32%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 173.34M
Earnings 15.37M
Profit Margin 8.87%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-50M
0
50M
100M
150M
-40.0%
-20.0%
0.0%

Analyst Insights

View More

Analyst Price Targets

2.00
2.00 Average
0.5734 Current
2.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/12/2024
Analyst Needham
Rating Action Reiterates
Rating Hold
Price Action --
Price Target --

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -15.50%

  • Return on Assets (ttm)

    3.00%

  • Return on Equity (ttm)

    -36.06%

  • Revenue (ttm)

    651.13M

  • Net Income Avi to Common (ttm)

    -100.92M

  • Diluted EPS (ttm)

    -0.3800

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    32.87M

  • Total Debt/Equity (mrq)

    224.80%

  • Levered Free Cash Flow (ttm)

    24.95M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: